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Radiotherapy is a treatment modality largely used for 
head and neck malignancies. However, high doses of 
radiation in large areas, including the oral cavity, maxilla, 
mandible and salivary glands may result in several undesired 
reactions. Mucositis, candidosis, disgeusia, radiation caries, 
osteoradionecrosis, soft tissue necrosis and xerostomia are 
some of radiotherapy’s complications. Aim: The aim of this 
study is to briefly review the side effects that may be seen 
in the oral cavity during or after radiotherapy treatment in 
the head and neck region. Basic method used: Review of 
relevant literature. Study design: Literature review. Results: 
Radiotherapy is still associated with several side effects, 
significantly affecting patients’ quality of life. Conclusions: 
A multidisciplinary treatment, including physicians, dentists, 
speech therapits, nutritionists, and psychologists, is the best 
alternative to minimize, or even prevent such reactions.
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INTRODUCTION
Every year, about 870,000 new cases of malignant 
tumors on the upper airways and digestive passages are 
diagnosed in the world.1  In developing countries, only 
neck cancer rates  are higher than the incidence rates of 
these malignancies.2  The choice treatment for these ma-
lignancies is surgery, associated or not to radiotherapy. 
Surgery and radiotherapy are the treatment options for the 
localized or regional disease. 3,4
 Many patients with head and neck cancer are 
submitted to high doses of radiotherapy in large areas 
including oral cavity, maxilla, mandible and salivary glan-
ds. Despite having the advantage of preserving the tissue 
structure, radiotherapy causes many adverse reactions in 
the oral cavity.5 Since radiotherapy-induced oral compli-
cations cause high morbidity and a decrease in quality of 
life, the aim of this review is to tackle the main adverse 
oral effects caused by radiotherapy.
 Biological aspects of radiotherapy
Radiotherapy is a treatment option for malign tu-
mors whose therapeutic agent is ionizing radiation, that is 
to say, the type of radiation that promotes ionization in the 
area in which it is applied, making it electrically unstable. 
Ionizing radiations are divided into the corpuscular and 
electromagnetic ones. Corpuscular radiations are represen-
ted by electrons, protons and neutrons; electromagnetic 
radiations are called photons, being represented by X rays 
and by gamma rays. In the clinical practice, most radiothe-
rapy treatments are done through the use of photons.6
Ionizing radiations act on the nuclear DNA leading 
to death or loss of its reproductive capacity. Since DNA 
content duplicates during mitosis, those cells with a high 
degree of mitotic activity are more radiosensitive than those 
with low mitotic rate. Radiation action can be direct or 
indirect. On the direct action, the DNA molecule is clea-
ved, interfering in the duplication process. On the indirect 
effect, water is dissociated into its two elements, H+ and 
OH; the latter reacts with the basis of DNA, interfering in 
the duplication process. Since water represents most part 
of cell content, the indirect effect is proportionally more 
important than the direct one.7
Due to the fact of being in a continuous multiplying 
process, malignant cells can suffer the radiation effects. 
However, the multiplying ability varies according to cell 
type. Thus, there is a radiosensitivity scale both for tumor 
and normal cells. Embryonic malignancies and lympho-
mas are radiosensitive tumors, whereas carcinomas are 
moderately radiosensitive.8
In order to express the amount of absorbed radia-
tion by the tissues, an international unit, rad (radiation 
absorbed dose) was initially proposed, that is to say, the 
difference between the applied radiation and that which 
went through the tissues. Recently, this unit was replaced 
by Gray, defined as 1 joule per kilogram. Gy is short for 
Gray, thus: 1 Gy = 100 cGy =100 rad.9,10
Radiotherapy can be administered in short duration 
schemes up to extremely long schemes, lasting for several 
weeks. The justification for applications in small daily 
fractions is based on radiobiology “5 Rs”: reoxygenation, 
redistribution, recruitment, repopulation and regeneration.6 
Most patients on radiotherapy receive a total dose of 50-70 
Gy as curative dose. These doses are fractioned during 
a period of 5-7 weeks, once a day, 5 days a week, with 
a daily dose of approximately 2Gy. On the concomitant 
treatment, 45c Gy are used on the pre-operative stage and 
55-60 Gy on the post-operative.11
Oral complications of radiotherapy
Adverse reactions to radiotherapy will depend on 
the volume and area being irradiated, on the total dose, on 
the fractioning, on the age, on the patient’s clinical condi-
tions and on the associated treatments. A small increase on 
tumor dosage is enough for a significant increase on the 
complications incidence. Acute reactions happen during 
the treatment and most of the time, they are reversible. 
Late complications are normally irreversible, leading to 
permanent incapability and to a worsening of quality of 
life5, and they vary on intensity, being normally classified 
into mild, moderate and severe.7
Many head and neck cancer patients are submitted 
to high doses of radiotherapy on large areas of radiation 
including the oral cavity, maxilla, mandible and salivary 
glands. Thus, anti-cancer therapy is associated with several 
adverse reactions. These reactions can occur in an acute 
stage (during or at the weeks right after treatment) or 
in a chronic stage (months or years after radiotherapy). 
The severity of acute oral complications will depend on 
the inclusion degree of these structures on the radiated 
area. 5,12
Mucositis
Mucositis is defined as a mucosal irritation.5 Anti-ne-
oplastic-therapy-induced mucositis is a significant adverse 
reaction that may interfere on the radiotherapy process 
altering the tumor local control and therefore, the patient’s 
survival. Mucositis is believed to occur in four stages (in-
flammatory/vascular, epithelial, ulcerative/bacteriologic 
and healing). The most used scale to measure oral mu-
cositis is the one by the WHO, which classifies mucositis 
into four degrees. Degree 0 is when there are no signs or 
symptoms. Degree 1 is when the mucosa is erythematose 
and painful. Degree 2 is characterized by ulcers, and the 
patient can eat normally. Degree 3 is when the patient has 
ulcers and can only drink fluids. Finally, degree 4 is when 
the patient cannot eat or drink. 13 
Due to oral mucosa damages, patients will complain 
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of pain, what may lead to the need of  using painkillers 
during treatment. The pain intensifies whenever the pa-
tient tries to eat or drink.5 Mucositis is even worse when 
chemotherapy is used in association with radiotherapy in 
cancer treatment.14
Candidosis
Radiated patients are more prone to developing 
oral infections caused by fungi and bacterias.15 Studies 
have showed that patients submitted to radiotherapy have 
a higher number of microbian species, such as Lactoba-
cillus spp., Streptococcos aureus and Candida albicans.9 
Oral candidosis is a common infection in patients being 
treated for upper airways and digestive tract malignancies. 
Colonization of oral mucosa can be found in as many as 
93% of these patients, whereas Candida infection can be 
found in 17-29% of patients submitted to radiotherapy. 
The increased risk for oral candidosis is likely to be the 
result of the drop in salivary flow as a consequence of 
radiotherapy.16,17 Besides, a possible explanation for a 
higher predisposition of irradiated patients to candidosis 
is a reduced phagocytic activity of salivary granulocytes 
against these micro-organisms.18 
Clinically, candidosis can be seen both in its pseu-
domembranous and erythematous forms. The latter can 
be of difficult diagnosis, and it may be confused with 
irradiation induced mucositis. Patients complain more of 
pain and / or burning sensation.16,17
Ramirez-Amador et al.17 verified that Candida pre-
valence in patients increased from 43% in the first visit to 
the doctor’s office to 62% during radiotherapy and finally 
to 75% during post-radiotherapy control visits. In the stu-
dy by Redding et al.19, 73% of patients analyzed showed 
colonization by Candida, whereas 27% of them had the 
infection. The study by Grotz et al.20 analyzed colonization 
by Candida in irradiated patients. They verified that the 
maximum colonization rate happened six months after 
radiotherapy, and 12 months after radiotherapy the values 
went back to be lower than normal.
Several studies have already analyzed which Candi-
da species were involved in colonization and infection of 
radiated patients. Previous studies16,17 showed that Candida 
albicans was the most prevalent micro-organism. However, 
other species had been identified recently. C. glabrata e 
C. krusei micro-organisms had already been seen in pa-
tients submitted to radiotherapy.21 Recent studies found 
a relation between oral candidosis and C. dubliniensis 
species. In this study, the authors suggest that the species 
C. albicans and C. dubliniensis probably act together in 
the infections that affect radiated patients.22,23 Besides, it 
is known that the non-albicans species distribution varies 
according to geographical location. Thus, in North Ame-
rica, the predominant species is C. glabrata. Whereas a 
study done in Brazil showed that the predominant species 
is C. tropicalis.24
Dysgeusia
Dysgeusia affects patients from the second or third 
week of radiotherapy onwards, and it may last for several 
weeks or even months. It occurs because the taste buds 
are radiosensitive, with the degeneration of their normal 
histological architecture. The increase of salivary flow 
viscosity and the saliva biochemical alteration creates a 
mechanical barrier of saliva which makes it difficult the 
physical contact between the tongue and foodstuff. The 
recovery until reaching almost normal levels generally 
takes place around 60 to 120 days after the end of the 
radiation. Studies show that dysgeusia is a complaint by 
approximately 70% of patients submitted to radiotherapy, 
also implying in the loss of appetite and weight, being 
the most uncomfortable complication for most radiated 
patients. 5,14,25
Radiation caries
Even patients who had not experienced tooth 
decay for some time, may develop radiation caries when 
submitted to radiotherapy.26 The main factor for the deve-
lopment of such injuries is the decrease of saliva amount 
and its qualitative alterations27 Besides, radiation has a 
direct effect on teeth, making them more susceptible to 
decalcification. 26
Osteoradionecrosis
Osteoradionecrosis (ORN) is a bone ischemic ne-
crosis caused by radiation, being one of the most serious 
consequences of radiotherapy, causing pain as well as 
possible substantial loss of bone structure5,28 Due to anti-
cancer therapy, bone cells and the vascularization of 
bone tissue may suffer irreversible injuries.26 ORN may 
occur spontaneously or more commonly, after trauma 
(generally dental extractions). In 95% of cases ORN is 
associated with soft tissue necrosis and subsequent bone 
exposure.28 Mandibles are more affected than maxillas 
and patients with their natural teeth have greater chances 
of developing ORN. Spontaneous bone exposure occurs 
approximately one year after finishing radiotherapy and the 
risk of developing this complication remains indefinitely.26 
Besides, studies show that approximately 60% of patients 
complain of pain, ranging from mild pain, controlled 
with drugs, to extremely painful conditions. However, 
the presence of these symptoms does not appear to be 
related to the extension of the process. ORN may also 
result in edema, suppuration and pathological fractures, 
which may occur in 15% of patients, always experienced 
together with pain.28
Soft tissue necrosis
Another possible consequence of radiotherapy is 
707
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 72 (5) SEPTEMBER/OCTOBER 2006
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
soft tissue necrosis, which may be defined as an ulcer 
located in the radiated tissue, without the presence of re-
sidual malignancy. The occurrence of soft tissue necrosis 
is related to dose, time and volume of the radiated gland, 
when the brachytherapy is used, the risk is higher. Soft 
tissue necrosis is a normally painful condition and good 
oral hygiene together with the use of painkillers and often 
times, antibiotics, are necessary to manage the condition. 
Since ulcerations are often seen on the tumor primary site, 
regular evaluations are necessary until the necrosis retreats, 
therefore excluding the possibility of recurrence. 26 Besides, 
soft tissues may suffer fibrosis after radiotherapy, becoming 
pale, thin and without flexibility. When fibrosis affects 
chewing musculature (temporal, masseter and pterygoid 
muscles) trismus can happen. In the most serious cases, 
trismus may interfere with eating and dental care. 5
Xerostomia
Xerostomia, or “dry mouth”, can result from some 
diseases or it can be an adverse reaction to some drugs. 
29 Among radiated patients in the head and neck area, it 
is one of the most frequent complains.30 Chencharick and 
Mossman25 noticed that 80% of radiated patients complain 
of xerostomia. However, the relation between the individu-
al perception of dry mouth and the real values of salivary 
flow havr not yet been completely defined.31 In some 
situations, there is a co-relation between reduced salivary 
flow and xerostomia complaint.32 However, in many cases 
there is not a relation between xerostomia and objective 
findings of salivary gland dysfunction - that is to say, pa-
tients without alterations of salivary flow may complain of 
mouth dryness. Patients with xerostomia complain of oral 
discomfort, taste loss, speech and swallowing difficulties.33 
Saliva also suffers qualitative alterations resulting from 
radiotherapy with decrease of amylase activity, buffer 
capacity and pH, with consequent acidification. There 
are also alterations of several electrolytes such as calcium, 
potassium, sodium and phosphate.32-26 Thus, individuals 
who were radiated are more susceptible to periodontal 
disease, rampant tooth decay and oral infections by fungus 
and bacteria. 15
Xerostomia treatment can be done through the use 
of mechanic/taste stimulants, saliva substitutes or systemic 
agents. 37,38 Alternative methods, such as acupuncture, had 
also been mentioned as treatment options for xerostomia. 
39 Generally speaking, stimulants and saliva substitutes only 
reduce xerostomia, without altering salivary flow. On the 
other hand, systemic agents besides reducing xerostomia, 
also decrease oral problems associated with salivary glands 
hypofunction, through the increase of salivary flow. Thus, 
the treatment of choice for radiotherapy-induced xeros-
tomia, should be through the use of systemic agents, and 
pilocarpine is the most studied one among them. Besides, 
studies show that systemic agents, such as pilocarpine, are 
more effective when used during radiotherapy.34,40 This has 
also been recently showed for betanechol, when the drug 
used concomitantly with radiotherapy is able to increase 
salivary flow at rest, right after the end of the radiotherapy 
treatment, besides decreasing the subjective complaint of 
dry mouth.41
CONCLUSIONS
Radiotherapy has been widely used in treating 
malignant lesions on the head and neck, with improve-
ment in patient survival rates. However, this therapy is 
still associated with several adverse reactions that affect 
patient quality of life significantly, and may even affect 
the progress of the treatment. Taking into account that 
the occurrence of head and neck cancer rates are proba-
bly going to be the same as last decades, it is extremely 
important that health professionals are familiarized with 
the complications that may result from anti-neoplastic 
treatments. Multidisciplinary treatment, including medical 
team, dental surgeons, speech therapists, nutritionists and 
psychologists, is the best option in order to minimize or 
even prevent such complications.
REFERENCES
 1. Parkin DM, Pisani P, Ferlay J. Estimates of worldwide incidence of 
eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
 2. Muir CS, Wagner G, Demaret E, Nagy-Tiborcz A, Parkin DM, Schla-
efer K, Villhauer-Lehr M, Whelan S. Directory of on-going research 
in cancer epidemiology 1986. IARC Sci Publ 1986;80:1-805.
 3. Mantravadi RV, Haas RE, Liebner EJ, Skolnik EM, Applebaum EL. 
Postoperative radiotherapy for persistent tumor at the surgical margin 
in head and neck cancers. Laryngoscope 1983;93:1337-40.
 4. Spaulding CA, Korb LJ, Constable WC, Cantrell RW, Levine PA. The 
influence of extent of neck treatment upon control of cervical lym-
phadenopathy in cancers of the oral tongue. Int J Radiat Oncol Biol 
Phys 1991;21:577-81.
 5. Spetch L. Oral complications in the head and neck irradiated patient. 
Introduction and scope of the problem. Supp Care Dent 2002;10:36-
9.
 6. Novaes PERS. Radioterapia. In: Brentani MM, Coelho FRG, Iyeyasu 
H, Kowalski LP, editores. Bases da oncologia. 1.ed. Sao Paulo: Ed. 
Marina; 1998.
 7. Murad AM, Katz A. Oncologia: bases clínicas do tratamento. 1.ed. 
Rio de Janeiro: Guanabara Koogan; 1996.
 8. Salvajoli JV, Souhami L, Faria SL. Radioterapia em oncologia. 1.ed. 
Rio de Janeiro: Ed. Médica e Científica Ltda.; 1999.
 9. Rothwell BR. Prevention and treatment of the orofacial complications 
of radiotherapy. JADA 1987;114:316-22.
10. Kowalski LP, Agnelli A, Salvajoli JV, Lopes LF. Manual de condutas 
diagnósticas e terapêuticas em oncologia. 2.ed. São Paulo: FAP; 
2002.
11. Tsujii II. Quantitative dose-response analysis of salivary function 
following radiotherapy using sequential RT-sialography. Int J Radiat 
Oncol Biol Phys 1985;11:1603-12.
12. Barasch A, Safford M, Eisenbeg E. Oral cancer and oral effects of 
anticancer therapy. Mt Sinai J Med 1998;65:370-7.
13. Pico JL, Avila-Gavarito A, Naccache P. Mucositis: its occurence, con-
sequences and treatment in the oncology setting. Oncol Phys Educ 
1998;3:446-51.
14. Ohrn KEO, Wahlin Y, Sjoden P. Oral status during radiotherapy and 
708
BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 72 (5) SEPTEMBER/OCTOBER 2006
http://www.rborl.org.br  /  e-mail: revista@aborlccf.org.br
chemotherapy: a descriptive study of patient experiences and the 
occurrence of oral complications. Supp Care Cancer 2001;9:247-57.
15. Hancock PJ, Epsten JB, Sadler GR. Oral and dental management 
related to radiation therapy for head and neck cancer. J Can Dent 
Assoc 2003;69:585-90.
16. Silverman S Jr, Luangjarmekorn L, Greenspan D. Occurrence of oral 
candida in irradiated head and neck cancer patients. J Oral Med 
1984;39:194-6.
17. Ramirez-Amador V, Silverman S Jr., Mayer P, Tyler M, Quivey J. Can-
didal colonization and oral candidiasis in patients undergoing oral 
and pharyngeal radiation therapy. Oral Surg Oral Med Oral Pathol 
Radiol Endod 1997;84:149-53. 
18. Ueta E, Osaki T, Yoneda K, Yamamoto T. Prevalence of diabetes 
mellitus in odontogenic infections and oral candidosis. J Oral Pathol 
Med 1993;22:168-74.
19. Redding SW, Pfaller MA, Messer SA, Smith JA, Prows J, Bradley LL, 
et al. Variations in fluconazole susceptibility and DNA subtyping 
of multiple Candida albicans colonies from patients with AIDS and 
oral candidiasis suffering one or more episodes of infection. J Clin 
Microbiol 1997;35:1761-5.
20. Grotz KA, Genitsariotis S, Vehling D, Al-Nawas B. Long term oral 
Candida colonization, mucositis and salivary function after head and 
neck radiotherapy. Supp Care Cancer 2003;11:717-21.
21. Mucke R, Kaben U, Libera T, Knauerhase H, Ziegler PG, Hamann 
D, Strietzel M. Fluconazole prophylaxis in patients with head and 
neck tumours undergoing radiation and radiochemotherapy. Mycoses 
1998;41:421-3.
22. Redding SW, Zellars RC, Kirkpatrick WR, Mcatee RK, Caceres MA, 
Fothergill AW, et al. Epidemiology of Oropharyngeal Candida colo-
nization and infection in patients receiving radiation for head and 
neck cancer. J Clin Microbiol 1999;37:3896-900.
23. Redding SW, Bailey CW, Lopez-Ribot JL, Kirkpatrick WR, Fothergill 
AW, Rinaldi MG, Patterson TF. Candida dubliniensis in radiation-
induced oropharyngeal candidiasis. Oral Surg Oral Med Oral Pathol 
Radiol Endod 2001;9:659-62.
24. Jham BC, Françca EC, Reis RR, Santos VR, Kowalski LP, Freire ARS. 
Candida oral colonization and infection in Brazilian patients under-
going radiotherapy in the head and neck: a pilot study. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endodontol. In press, 2006.
25. Chencharick JD, Mossman KL. Nutritional consequences of the ra-
diotherapy of head and neck cancer. Cancer 1983;51:811-5.
26. Silverman, S.Jr. Oral cancer. Complications of therapy. Oral Surg Oral 
Med Oral Pathol Oral Radiol Endond 1999;88:122-6.
27. Epstein JB, Chin EA, Jacobson JJ, Rishiraj B, Le N. The relationships 
among fluoride, cariogenic oral flora, and salivary flow during ra-
diation therapy. Oral Surg Oral Med Oral Pathol 1998;86:286-92.
28. Thorn JJ, Hansen HS, Spetch L, Bastholt L. Osteoradionecrosis of the 
jaws: clinical characteristics and relation to field of irradiation. J Oral 
Maxillofac Surg 2000;58:1088-93.
29. Porter SR, Scully C, Hegarty AM. An update of the etiology and ma-
nagement of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol 
Endod 2004;97:28-46.
30. Guchelaar HJ, Vermes A, Meerwaldt JH. Radiation induced xeros-
tomia: pathophysiology, clinical course and supportive treatment. 
Support Care Cancer 1997;5:281-8.
31. Logemann JA, Smith CH, Pauloski BR, Rademaker AW, Lazarus CL, 
Colangelo LA, et al. Effects of xerostomia on perception and perfor-
mance of swallow function. Head and Neckm, 2001;23:317-21.
32. Pow EHN, Mcmillan AS, Leung WK, Wong MCM, Kwong DL. Salivary 
gland function and xerostomia in southern Chinese following radio-
therapy for nasopharyngeal carcinoma. Clin Oral Invest 2003;7:230-
4.
33. Davies AN, Broadley K, Beighton D. Salivary gland hypofunction in 
patients with advanced cancer. Oral Oncol 2002;38:680-5.
34. Makkonen TA, Tenovuo J, Vilja P, Heimdahl A. Changes in the protein 
composition of whole saliva during radiotherapy in patients with oral 
or pharyngeal cancer. Oral Surg Oral Med Oral Pathol 1986;62:270-
5.
35. Almstahl A, Wikstrom M, Stenberg I, Jakobsson A, Fagerberg-Mohlin 
B. Oral microbiota associated with hyposalivation of different origins. 
Oral Microbiol Imunol 2003;18:1-8.
36. Möller P, Perrier M, Ozsahin M, Monnier P. A prospective study 
of salivary gland function in patients undergoing radiotherapy for 
squamous cell carcinoma of the oropharynx. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod 2004;97:173-89.
37. Davies AN. The management of xerostomia:a review. Eur J Cancer 
Care 1997;6:209-14.
38. Amerongen AVN, Veerman ECI. Current therapies for xerostomia and 
salivary gland hypofunction associated with cancer therapies. Supp 
Care Cancer 2003;11:226-31.
39. Johnstone PAS, Peng P, Byron CM, Inouye WS, Niemtzow RC. 
Acupunture for pilocarpine-resistant xerostomia following radiothe-
rapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 
2001;50:353-7.
40. Davies AN, Singer J. A comparison of artificial saliva and pilocarpine 
in radiation induced xerostomia. J Laryngol Otol 1994;108:663-5.
41. Jham BC, Teixeira IV, Aboud CG, Carvalho AL, Coelho MM, Freire 
ARS. A randomized phase III prospective trial of bethanechol to 
prevent radiotherapy-induced salivary gland damage in patients with 
head and neck cancer. Oral Oncol. In press 2006.
